SCHEMBL309237

SCHEMBL309237

CCCCCn1ncc2c(N)cccc21

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 8/20 0.50
SLC9A1 P19634 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6118555 0.89 SLC9A1 (0.40) TLR8SLC9A1
SCHEMBL30861053 0.82 DDB1 (0.42) TLR8SLC9A1
SCHEMBL6125557 0.82 DDB1 (0.42) TLR8SLC9A1
SCHEMBL309493 0.82 GRM2 (0.51) TLR8SLC9A1
SCHEMBL23412841 0.81 HTR2A (0.44) TLR8
SCHEMBL29780607 0.81 HTR2A (0.44) TLR8
SCHEMBL1741552 0.79 PKM (0.39)
SCHEMBL6118603 0.79 KEAP1 (0.41)
SCHEMBL1743210 0.79 PKM (0.39)
SCHEMBL3349561 0.79 MPO (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP claimed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US claimed
EP-1869003-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-26 EP claimed
WO-2006108699-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2006-10-19 WO claimed
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
EP-2013185-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-05-30 EP disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
EP-2081910-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-02-01 EP disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-7947727-B2 Compounds GlaxoGroupLimited (GB) 2011-05-24 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-20100120883-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-05-13 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
EP-2013185-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2009-01-14 EP disclosed
WO-2008043789-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-17 WO disclosed
WO-2008043788-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-17 WO disclosed
EP-1869003-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-26 EP disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
WO-2007122165-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-01 WO disclosed
WO-2006108699-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, MC2R TLR8 992/4885SLC9A1 816/4885
US-20100120883-A1 NOVEL COMPOUNDS TSLP, LTB4R2, LTB4R TLR8 156/4885SLC9A1 3873/4885
US-20070265326-A1 NOVEL COMPOUNDS CCL11, MRGPRX2, LTB4R2 TLR8 196/4885SLC9A1 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.